Compare Albertsons Companies Inc (ACI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Albertsons Companies Inc trades at $12.15 (market cap $5.95B), while State Street SPDR S&P Biotech ETF trades at $159.05. The key difference: Albertsons Companies Inc pays a 5.55% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Albertsons Companies Inc nearer its low. Which is the better fit depends on your goals.
| ACI | XBI | |
|---|---|---|
Market Cap | $5.95B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $19.74 | $164.28 |
52-Week Low | $11.03 | $86.92 |
Enterprise Value | $21.35B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons Companies (ACI) trades at $12.135, showing minimal daily movement with a 0.04% gain. The stock faces bearish technical signals despite recent insider buying by the CEO and CFO. Fundamentals reveal declining profitability with net income margin at just 0.08% and falling revenue growth, though valuation metrics like P/S of 0.08 appear attractive. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple law firm investigations into potential securities violations.
ACI presents a high-risk opportunity with conflicting signals. While insider purchases and low valuation multiples suggest potential value, deteriorating margins, earnings misses, and legal scrutiny create significant headwinds. The stock's near-term trajectory depends on successful execution of the ACI Edge restructuring and digital initiatives to reverse profitability declines.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
